BioArctic AB Class B BIOA B

STO: BIOA B | ISIN: SE0010323311   13/06/2025
198,40 SEK (-1,59%)
(-1,59%)   13/06/2025

15 mei 2025 · Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 - March 2026) · Persbericht

13 mei 2025 · Invitation to presentation of BioArctic's first quarter report for January - March 2025 on May 21 at 9.30 a.m. CET · Persbericht

8 mei 2025 · Exidavnemab phase 2a study expanded to include MSA patients · Persbericht

1 april 2025 · The European Commission refers lecanemab decision to Appeal Committee · Persbericht

25 maart 2025 · BioArctic's partner Eisai presents sales simulation for Leqembi® at its annual press conference · Persbericht

17 maart 2025 · BioArctic receives Orphan Drug Designation for exidavnemab the US · Persbericht

12 maart 2025 · Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University's Innovation and Entrepreneurship Prize · Persbericht

3 maart 2025 · Therapeutic Goods Administration decides not to register lecanemab in Australia · Persbericht

27 augustus 2024 · Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology · Persbericht

22 augustus 2024 · Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain · Persbericht

22 augustus 2024 · Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic · Persbericht

19 augustus 2024 · Invitation to presentation of BioArctic's second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET · Persbericht

14 augustus 2024 · Leqembi approved for the treatment of Alzheimer's disease in the United Arab Emirates · Persbericht

1 augustus 2024 · Leqembi revenue more than doubled - totaled JPY 6.3 billion in the second quarter 2024 · Persbericht

30 juli 2024 · Long-term lecanemab data show increased patient benefit with maintained safety profile · Persbericht

26 juli 2024 · Eisai will seek re-examination of CHMP opinion för lecanemab · Persbericht

26 juli 2024 · CHMP has adopted a negative opinion on lecanemab for the EU · Persbericht

23 juli 2024 · Long-term treatment data for lecanemab to be presented at AAIC 2024 · Persbericht

12 juli 2024 · Leqembi approved for the treatment of Alzheimer's disease in Israel · Persbericht

11 juli 2024 · Leqembi approved for the treatment of Alzheimer's disease in Hong Kong · Persbericht

Mijn selecties